Plain-English translation of NCT06616155 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing whether , a newer medication, works better when combined with for men with advanced prostate cancer that has become resistant to standard hormone therapy. The study involves about 20 patients and focuses on understanding how safe and effective this medication combination is. Researchers will monitor your response to treatment and collect blood samples and imaging scans throughout the study.
Some men's prostate cancer stops responding to standard treatments like abiraterone. This study is exploring whether the medication combination might help patients whose cancer has become resistant to these earlier therapies.
You likely qualify if…
You likely don't qualify if…
You would take two medications by mouth: twice daily and once daily, in 28-day cycles that repeat as long as your cancer doesn't progress and you tolerate the treatment well. Throughout the study, you'll have regular blood draws, CT scans, and bone scans to monitor how your cancer responds. You may also be asked to undergo a biopsy of a cancer site to help researchers understand how the medication is affecting your tumor at a cellular level.
AI-generated summary from trial data · Jun 9, 2026 · Not medical advice
United States